| 3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off | 07/15 09:00 | investorplace.com |
| eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq | 06/24 07:00 | globenewswire.com |
| eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer | 05/20 08:30 | globenewswire.com |
| EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024 | 05/09 22:56 | investorplace.com |
| eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | 05/09 16:01 | globenewswire.com |
| eFFECTOR Therapeutics to Participate in Upcoming Investor Conference | 04/09 08:00 | globenewswire.com |
| eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails | 04/05 14:01 | zacks.com |
| eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer | 04/04 08:30 | globenewswire.com |
| eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | 03/25 16:01 | globenewswire.com |
| eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference | 02/05 08:30 | globenewswire.com |